Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

14 results
Display

Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma

Cho SH, Lee JS, Yun HJ, Lee YS, Chang HS

Papillary thyroid carcinoma is the most common type of thyroid cancer, for which surgery following preoperative staging and risk assessment is the standard treatment. Afatinib is an orally active irreversible...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ

PURPOSE: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Olmutinib Induced Lichen Planus Like Eruption

Oh SH, Byun HJ, Oh SJ, Jun JY, Park JH, Lee JH, Lee DY, Lee JH, Yang JM

Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric eruption of erythematous or violaceous plaques resembling lichen planus on the trunk...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer

Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, Han JY

PURPOSE: This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

Lee Y, Han JY, Moon SH, Nam BH, Lim KY, Lee GK, Kim HT, Yun T, An HJ, Lee JS

PURPOSE: Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis

Hong SH, Kim YS, Lee JE, Kim IH, Kim SJ, Han D, Yoo IR, Chung YG, Kim YH, Lee KY, Kang JH

PURPOSE: The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib

Park DI, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, Chung CU, Kim SS, Seo JH, Lee JE

BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Patient with Lung Adenocarcinoma with Double Rare EGFR Mutation of G719C and L861Q

Yun JT, Kim GJ, Kim SY, Jeong JW, Park SY, Yang YJ, Park JC

The vast majority of epidermal growth factor receptor (EGFR) gene mutations are detected in lung adenocarcinoma. EGFR mutations are the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer

Choi M, Lee Y, Hwang SH, Lee JS

Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells

Yang Z, Ahn HJ, Nam HW

Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lee JC, Jang SH, Lee KY, Kim YC

  • KMID: 2167612
  • Cancer Res Treat.
  • 2013 Jun;45(2):79-85.
Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Inhibitors and Overcoming Strategies in Lung Cancer

Choi CM, Lee JC

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib show good response and survival benefit in EGFR-mutant lung cancer, acquired resistance inevitably develops which limits...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI

Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr